Skip to search formSkip to main contentSkip to account menu

Lomoparan

National Institutes of Health

Related topics

Related topics

1 relation
danaproid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1997
Review
1997
[Thrombopenia induced by heparin. From physiopathology to treatment].
Heparin-induced thrombocytopenia is an uncommon but potentially dangerous adverse effect of heparin therapy. Late onset… 
1997
1997
Cardiopulmonary bypass using lomoparan: monitoring of anticoagulation using anti-Xa levels and thromboelastography.
1993
1993
Thrombopénie à l’héparine: Utilisation d’un héparinoide de bas poids moléculaire, Org 10172 (Lomoparan)
1992
1992
A cross-over comparison of the pharmacokinetics of three low molecular weight (LMW) heparins and lomoparan (ORG 10172)
1991
1991
Influence of Chlorthalidone on the Pharmacokinetics and Pharmacodynamics of Org 10172 (Lomoparan®), A Low Molecular Weight Heparinoid, in Healthy Volunteers
The influence of chlorthalidone (100 mg po) on the pharmacokinetics and pharmacodynamics of Org 10172 (IV bolus injection of 3250… 
Review
1991
Review
1991
Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
1991
1991
Partial in vivo neutralisation of plasma anticoagulant effects of Lomoparan (Org 10172) by protamine chloride.
1991
1991
The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.
1. We have investigated the effect of repeated s.c. Org 10172 (a low molecular weight heparinoid; Lomoparan) treatment (1000 anti… 
1990
1990
Results of compassionate (named patient) use of the low molecular weight anticoagulant Org 10172 (Lomoparan)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)